Oncology contributes five high signal trials in Trial Watch Edition 14.
AstraZeneca is testing Datopotamab Deruxtecan with Rilvegostomig in high risk muscle invasive bladder cancer, combining a TROP2 ADC with a PD 1 and TIGIT bispecific in the adjuvant setting.
AbbVie is advancing Pivekimab Sunirine with venetoclax and azacitidine in newly diagnosed AML, while Innovent is testing IBI363, a PD 1 and IL 2 bispecific, in refractory advanced colorectal cancer.
The category also includes vorasidenib in IDH mutant grade 3 astrocytoma and TR115 in relapsed or refractory peripheral T and NK cell lymphoma.